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EH Pieter van Dijkhuizen1,2* and Nico M Wulffraat1Abstract
Background: Methotrexate (MTX) is the cornerstone disease-modifying anti-rheumatic drug in juvenile idiopathic
arthritis (JIA). In JIA, it is important to start effective treatment early to avoid long-term sequelae, such as joint
damage. To accomplish this goal, it is crucial to know beforehand who is going to respond well to MTX. In addition,
MTX adverse effects such as MTX intolerance occur frequently, potentially hindering its efficacy. To avoid inefficacy
of an otherwise effective drug, the physician should be timely aware of these adverse events. Consequently, to
optimise treatment of JIA patients with MTX, predictors for efficacy and adverse events should be used in daily
clinical practice. The aim of this study was to summarise the existing knowledge about such predictors.
Methods: A systematic literature search was performed in PubMed, Embase and The Cochrane Library, and 1,331
articles were identified. These were selected based on their relevance to the topic and critically appraised according to
pre-defined criteria. Predictors for MTX efficacy and adverse events were extracted from the literature and tabulated.
Results: Twenty articles were selected. The overall quality of the studies was good. For MTX efficacy, candidate predictors
were antinuclear antibody positivity, the childhood health assessment questionnaire score, the myeloid-related protein
8/14 level, long-chain MTX polyglutamates, bilateral wrist involvement and some single nucleotide polymorphisms
(SNPs) in the adenosine triphosphate binding cassette and solute carrier transporter gene families. For MTX adverse
events, potential predictors were alanine aminotransferase and thrombocyte level and two SNPs in the γ-glutamyl
hydrolase and methylenetetrahydrofolate reductase genes. However, validation of most predictors in independent
cohorts was still lacking.
Conclusions: Interesting candidate predictors were found, especially for MTX efficacy. However, most of these were
not validated. This should be the goal of future efforts. A clinically relevant way to validate the predictors is by means
of creating a clinical prediction model.
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PredictionBackground
Juvenile Idiopathic Arthritis (JIA) is the most common
childhood rheumatologic disorder, with a prevalence of
16–150 per 100,000 children. It is characterised by chronic
arthritis of unknown aetiology, lasting at least 6 weeks,
with an onset before 16 years of age [1]. JIA is a heteroge-
neous group of disorders, whose manifestations range* Correspondence: E.H.P.Dijkhuizen@umcutrecht.nl
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article, unless otherwise stated.from relatively mild inflammation of a single joint, to se-
vere involvement of multiple joints lasting into adulthood
and leading to structural joint damage and incapacity.
These long-term sequelae should be avoided and it is
thought that early and effective therapy in the so-called
window of opportunity is crucial in doing so [2-4].
The most widely used disease-modifying anti-rheumatic
drug (DMARD) in the treatment of JIA is methotrexate
(MTX), which has been used for more than 25 years. It is
an inexpensive and safe drug and is beneficial in around
70% of JIA patients [5,6]. Other treatment options includeBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cals for MTX or corticosteroid resistant cases. It is still
impossible to predict the individual prognosis and hence
the treatment requirements at the onset of the disease [7],
leading to the current step-up approach of starting MTX
and adding a biological if the patient does not respond
sufficiently well to MTX monotherapy. However, given
the abovementioned goal to start effective treatment im-
mediately in order to prevent joint damage and the fact
that MTX monotherapy is completely ineffective in
around 30% of patients, it is essential to know beforehand
who is going to respond well to MTX and who is not. The
latter group may then be prescribed a biological from the
outset.
Next to drug effectiveness, its side effects should be
taken into account. It has been shown previously that
MTX despite being safe frequently causes transient ele-
vation of liver enzymes and potentially also cytopenias,
for which periodic evaluation of blood counts and liver
function tests are advised [6,8]. Perhaps more import-
antly, gastrointestinal side effects and MTX intolerance
occur frequently [9-12]. MTX intolerance has been
shown to influence the quality of life of patients nega-
tively [13]. Furthermore, these adverse effects potentially
cause non-compliance and hence ineffectiveness of an
otherwise effective drug [9,12,14,15], interfering with the
goal to induce early disease remission. To avoid this
problem, the risk of occurrence of these adverse effects
should be known early, in order for the physician to
intervene timely.
Therefore, to optimise treatment of JIA patients, it is
necessary to predict the probability of response as well
as the risk of developing adverse events. This systematic
literature review aims to find and summarise studies,
which assessed factors capable of doing so.
Methods
On 20 April 2014, a systematic literature search was per-
formed in PubMed, Embase and The Cochrane Library,
without any publication date or language constraints. Using
the algorithm in Table 1 to retrieve all papers regarding JIA
and MTX, 1,331 articles were identified (Figure 1). These
were then screened for applicability to the researchTable 1 Search strategya
Search algorithm
#1 “Juvenile idiopathic arthritis” OR “juvenile chronic arthritis” OR “juvenile r
rheumatic arthritis” OR “childhood arthritis” OR “juvenile arthritis” OR JIA
#2 Methotrexate OR MTX OR “disease-modifying antirheumatic drug” OR “d
drugs” OR “disease-modifying anti rheumatic drug” OR “disease-modifyin
OR DMARDs
#3 #1 AND #2
aSearch performed on 20 April 2014.
bIn PubMed and Embase terms were searched in title and abstract only.
cIn The Cochrane Library terms were searched in title, abstract and keywords only.subject, the identification of predictors of MTX efficacy
and adverse effects (outcome) in JIA patients (domain).
Based on the title and the abstract, 45 articles were se-
lected for full-text screening (Figure 1). To ensure that all
relevant articles had been found, references of selected ar-
ticles were screened to identify any missed papers.
Selected articles were critically appraised, using prede-
fined criteria (Table 2). Studies that were selected, aimed
to find predictors for MTX efficacy or side effects within
6 months after the start of therapy in JIA patients, using
standardised outcome criteria.
The assessed predictors in the selected studies were
summarised in tabular form. Because of the high num-
ber of studies and predictors, it was decided to show the
direction of the effect of each predictor only, instead of
providing an odds ratio and 95% confidence interval. A
cut point of P <0.05 was defined to denote significance.
Even though some of the assessed studies aimed at con-
structing a prediction model, for which this cut point is
not important, we report significant predictors (P <0.05)
only.
Results
After full-text screening, 20 original research papers and
3 reviews were selected (Figure 1), of which the former
were critically appraised (Table 2). The overall relevance
and validity of the selected papers was good, leading to
only a few papers being excluded from the analysis. No
study described whether all patients were eligible to re-
ceive the same treatment, but we knew this was the case
in our own studies and assumed it was the case in all
other studies. Hardly any article described if the phy-
sician and researchers were blinded for the outcome at
the time of predictor determinations. Follow up was only
short term (<1 year) in almost all studies.
MTX efficacy
Fifteen studies assessed MTX efficacy, of which some
used a derivation cohort and an independent replication
cohort. Since these were independent cohorts, results
obtained in these cohorts were reported as if obtained
in separate studies. In most of the studies, MTX was
started within a median time of 1.5 years after diseasePubMedb Embaseb Cochranec
heumatoid arthritis” OR “juvenile
OR JCA OR JRA
7,844 10,906 296
isease-modifying antirheumatic
g anti rheumatic drugs” OR DMARD
34,919 50,157 5,251
662 1,229 64
Figure 1 Flow chart. Flow chart of the article selection procedure. Abbreviations: DDO, domain, determinant and outcome.
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American College of Rheumatology (ACR) response cri-
teria. Follow up ranged from 6 months to 1 year, but
was as much as 7.3 years in one study (Table 3).
The results of these studies are shown in Additional
file 1: Table S1. Demographics, as well as JIA categories,
were analysed extensively and were not predictive in
almost all studies. Disease activity parameters showed
inconsistent results in general, but the childhood health
assessment questionnaire (CHAQ) score was a potential
predictor. The same held true for the physician’s global
assessment (PGA), although less convincingly so. The in-
volvement of individual joints was assessed in too few
studies to be conclusive, but bilateral wrist involvement
was a potential predictor. Among laboratory data, positive
antinuclear antibody (ANA) was a predictor of better re-
sponse in three studies. Other interesting predictors could
be long-chain MTX polyglutamates (PGs), the myeloid-
related protein (MRP) 8/14 (also known as S100A8/A9),
the pro-inflammatory molecule osteopontin, or even the
haemoglobin level, although these were assessed in only
one study each (Additional file 1: Table S1).
Next to these predictors, many single-nucleotide poly-
morphisms (SNPs) were analysed. These were SNPs in
genes involved in the MTX metabolic pathway and in
genes with altered post-treatment gene expression. More-
over, recently a genome-wide analysis study (GWAS) was
published [22]. Of the latter study, only gene regions
showing association with MTX response could be re-
ported in this review.Overall, no unequivocal predictive SNP has been
found yet, because many were assessed in only one
study, or were predictive in one study and showed no ef-
fect in others. However, some SNPs (rs1045642, rs35592
and rs4793665) in the B1, C1 and C3 members of the
adenosine triphosphate binding cassette (ABC) trans-
porter family, and others (rs3763980 and rs1051266) in
the 16A7 and 19A1 members of the solute carrier (SLC)
transporter family were interesting. Furthermore, the
gene regions associated in the GWAS study were pro-
mising predictors (Additional file 1: Table S1).
In all, many potential predictors for MTX efficacy
were assessed, yielding some interesting candidates,
which, however, were analysed in too few studies to
draw a firm conclusion yet.
MTX adverse events
Seven of the selected studies assessed MTX adverse
events (Table 3). The assessed outcome varied from
overall adverse events to single adverse events such as
liver toxicity, gastrointestinal complaints or MTX in-
tolerance measured with the Methotrexate Intolerance
Severity Score (MISS) [9]. None of the articles focused
on (serious) infections. Since the outcome MTX adverse
events is a composite of all these outcomes, all studies
were included. Follow up ranged from 6 months to a
mean of 58.2 months.
Many predictors were evaluated in only one or two
studies, making the results inconclusive. However, inte-
resting predictors were the alanine aminotransferase
Table 2 Critical appraisal
Reference Design Relevance Validity
Dom Det Out Blind Rec SoC Loss Mis
Outcome: MTX efficacy
[16] Retrospective (validation prospective) + + +/− + + + + +
[17] Mixed retrospective and prospective + + +/− + + + + +
[18] Prospective + + +/− + + + + ?
[19] Prospective + + +/− +/− + ? ? +
[20] Cross-sectional + + +/− +/− + ? ? +
[10] Retrospective + + +/− ? + ? + +
[21] Retrospective + + +/− ? + ? ? +
[22] Mixed retrospective and prospective + +/− +/− ? + ? + +
[23] Prospective (validation unknown) + +/− +/− ? + ? ? ?
[24] Prospective (validation unknown) + +/− +/− ? + ? ? ?
[25]a Retrospective +/− +/− + ? + ? +/− +
[26] Prospective +/− + +/− ? + ? + +
[27] Prospective +/− + +/− ? + ? + +/−
[28] Prospective +/− + +/− ? + ? + ?
[29] Retrospective +/− +/− + ? + ? +/− +
[25]b Retrospective +/− +/− +/− ? + ? +/− +
[30] Retrospective + + - ? + ? + +
[31] Cross-sectional + + - +/− + ? ? ?
[32] Retrospective + +/− - +/− + ? ? ?
[33] Retrospective +/− + - ? + ? ? +
Outcome: MTX adverse effects
[34] Prospective + + +/− + + + + +
[18] Prospective + + +/− + + + ? ?
[10] Retrospective + + +/− ? + ? + +
[21] Retrospective + + +/− ? + ? ? +
[20] Cross-sectional + + +/− +/− + ? ? +
[31] Cross-sectional + + +/− +/− + ? ? ?
[32] Retrospective + +/− +/− +/− + ? ? ?
[35] Cross-sectional - + + ? - ? + +
Abbreviations: Blind blinding, Det determinant, Dom domain, Loss loss to follow up, Mis missing predictors, Out outcome, Rec recruitment, SoC standardization of care.
Bold articles were excluded for analysis.
aPredictors after 6 months for outcome after 5 years; bPredictors at baseline for outcome after 6 months.
Criteria: Domain: + Children with confirmed JIA, according to currently valid ILAR criteria, starting MTX +/− Children with JCA/JRA according to previously valid
criteria, or children with JIA and additional criteria (e.g. hospitalized, specific categories only), starting MTX - Children without JIA/JCA/JRA, or no MTX; Determinant: +
Prediction model or single predictors corrected for confounding in multivariable analysis +/− Single predictors in univariate analysis - No predictors; Outcome: + Efficacy:
Any standardized outcome measurement, follow up >1 year. Adverse effects: Any outcome measurement, follow up >1 year +/− follow-up <1 year - Efficacy: No use of
standardized outcome criteria; Blinding: + Both patient and physician blinded (or not applicable in case of objective measurements) +/− Patient or physician not
blinded - Not blinded; Recruitment: + Predictors determined at time of start of MTX or <6 months (or time of determination does not matter as in genetic evaluations,
gender, age at onset, etc.) +/− Predictors determined more than 6 months after start of MTX, but <1 year - Predictors determined after 1 year, or completely at random;
Standardization of care: + All participants treated according to standards of care - No standardized care; Loss to follow up (missing outcome): + <20% and unselective
loss to follow up; or >20%, unselective and solved with a statistically valid method (imputation) +/− >20% (not imputed) but unselective loss to follow up - Selective loss
to follow up; Missing predictors: + <20% and unselective; or >20%, unselective and solved with a statistically valid method (imputation) +/− >20% (not imputed) but
unselective - Selective missing predictors.
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in the γ-glutamyl hydrolase (GGH) gene, involved
in the breakdown of MTX PGs, and another SNP
(rs1801133) in the methylenetetrahydrofolate reductase(MTHFR) gene, involved in the folate metabolism. Fi-
nally, the polyarticular categories could potentially pose
a risk to develop MTX side effects (Additional file 2:
Table S2).
Table 3 Characteristics of included studies
Reference Design Country of origin N Inclusion criteria Outcomea Follow up
[18]b Prospective The Netherlands 113 JIA, starting MTX 1k, 2a, 2d, 2f 1 y
[19] Prospective UK 87 JIA, starting MTX 1b, 1j 6 mo
[17]c Retrospective and prospective The Netherlands 287 JIA, starting MTX 1c 1 y
[10] Retrospective Germany 411 JIA, starting MTX 1a, 1b, 1c, 2i 1 y
[16] (deriv) Retrospective The Netherlands 183 JIA, starting MTX 1e 1 y
[16] (rep) Prospective The Netherlands 104 JIA, starting MTX 1e 1 y
[23] (deriv)d Prospective UK 197 JIA, starting MTX 1d 6 mo
[23] (rep)d Unknown USA 210 JIA, starting MTX 1g 6 mo
[31] Cross-sectional Japan 92 JIA, at least 3 mo MTX 2e Mean 58.2 moe
[24] (deriv)d Prospective UK 197 JIA, starting MTX 1d 6 mo
[24] (rep)d Unknown USA 210 JIA, starting MTX 1g 6 mo
[20] Cross-sectional Czech Republic 69 JIA, at least 3 mo MTX 1i, 2d, 2f, 2g, 2h Median 1.3-1.4 ye
[28]f Prospective Multinational (PRINTO) 563 RF negative polyarticular course JIA,
starting MTX
1a, 1c 6 mo
[26] Prospective Italy 60 JIA, ≥2 active joints in
oligo persistent, ≥5 active joints in
other categories
1b 1 y
[27]f Prospective Multinational (PRINTO) 521 RF negative polyarticular course JIA,
starting MTX
1l 6 mo
[25] Retrospective Italy 125 Polyarticular JIA, starting MTX 1f, 1i 6 mo, 5 y
[32] Retrospective Germany 58 JIA, at least 3 mo MTX 2d, 2i Mean 48 months
[21] Retrospective Italy 80 JIA, at least 6 mo MTX 1a, 2c, 2g Efficacy: 6 mo
Toxicity: median 6–9 mo
[29] Retrospective USA 49 JRA, starting MTX 1h Mean 2.6 y (range 1.0-7.3 y)
[34]b Prospective The Netherlands 152 JIA, starting MTX 2b 1 y
[22] Retrospective and prospective Czech Republic, UK, The Netherlands 694 JIA, starting MTX 1f 6 mo
Abbreviations: ACR30/50/70 American College of Rheumatology pediatric 30, 50 or 70 response criteria, respectively, AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, CHQ child health
questionnaire, deriv derivation cohort, GI gastrointestinal, HRQOL health-related quality of life, JADAS juvenile arthritis disease activity score, JIA juvenile idiopathic arthritis, min minutes, MISS methotrexate intolerance
severity score, mo months, MTX methotrexate, NR non-response, PhS physical component summary score, PsS psychosocial component summary score, RA rheumatoid arthritis, rep replication cohort, RF rheumatoid
factor, ULN upper limit of normal, y years.
a1a: Achievement of ACR30; 1b: Achievement of ACR50; 1c: Achievement of ACR70; 1d: Achievement of ACR70 vs. non-achievement of ACR30; 1e: Achievement of ACR70 in 2/3 visits; 1f: NR vs. ACR30 vs. ACR50 vs.
ACR70; 1g: >70% improvement in joint count vs. <30%; 1h: Adapted ACR criteria for RA: morning stiffness <15 min, no fatigue, no joint swelling, no joint pain for 2 consecutive months; 1i: Clinical inactive disease on
MTX monotherapy according to Wallace criteria; 1j: JADAS-10; 1k: JADAS-27; 1l: HRQOL: CHQ PhS ≥30 and PsS ≥30; 2a: MISS: intolerant (score >6); 2b: MISS: intolerant (score >6) after 6 and/or 12 months; 2c: ALT/AST
> ULN; 2d: ALT/AST >2 ULN; 2e: ALT >5 ULN; 2f: Bone marrow suppression (any cytopenia); 2g: GI toxicity; 2h: Other (alopecia, headaches, behavioural changes, nodulosis); 2i: Any AE; bThis is the same cohort as the
replication cohort of [16], but different outcome and/or predictors; cThis cohort is the derivation and replication cohort of [16] together, but uses a slightly different outcome and different predictors; dThese are the
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This systematic literature review aimed to find predictors
for MTX efficacy and adverse events in JIA patients. For
MTX efficacy, many candidate predictors were investi-
gated, and some interesting results were found, such as
ANA positivity, the CHAQ score, the MRP 8/14 (S100A8/
A9) level, long-chain MTX-PGs, bilateral wrist involve-
ment, osteopontin level, haemoglobin, some SNPs in the
ABC and SLC transporter gene families and several gene
regions elucidated in the recently published GWAS. Most
of these variables have not yet been validated in indepen-
dent cohorts. Therefore, future efforts should be directed
at validating these candidate predictors. A clinically rele-
vant way to do so consists in combining these predictors
into a prediction model and assessing the prognostic ac-
curacy of the model. Thus far, only one prediction model
for MTX efficacy in JIA patients has been developed, con-
taining the erythrocyte sedimentation rate and four SNPs
in genes involved in the MTX metabolic pathway [16].
This model could be improved using the abovementioned
candidate predictors. The advantage of this method is
twofold: statistically, the selection of predictors for the
model in the independent cohort will be literature-driven,
instead of data-driven, leading to a reduction in the so-
called optimism [35]. Clinically, physicians will have an
easy-to-use tool at hand to determine the probability of
MTX efficacy in individual patients, allowing them to start
MTX in patients with a high probability of responding
and to initiate biologicals in those with a low probability
of responding. The clinical benefit of this approach should
ideally be estimated in a randomized clinical trial.
Regarding MTX adverse events, the results were less
clear. Although some interesting candidate predictors
were found, such as ALT and thrombocyte level and two
SNPs in the GGH and MTHFR genes, here too, vali-
dation of these was lacking. Furthermore, it seemed
questionable if these predictors would be sufficient to
predict the individual patients’ risk of developing MTX
adverse effects. Consequently, future efforts should be
directed both at validating existing candidate predictors
and at finding new predictors. These too should be com-
bined in a clinical prediction model (an example has
been submitted: Van Dijkhuizen EHP, Bulatovic Calasan
M, Pluijm SMF, De Rotte MCFJ, Vastert SJ, Kamphuis S,
De Jonge R, Wulffraat NM: Prediction of Methotrexate
Intolerance in Juvenile Idiopathic Arthritis, submitted).
Such a tool could be used to monitor high-risk patients
more closely, intervening as soon as adverse events
occur, for example by lowering the dose, stopping MTX
temporarily or prescribing other drugs. On the other
hand, low-risk patients could be saved the burden of fre-
quent checks.
Recently, a review was published about genetic predic-
tors of MTX efficacy and toxicity in rheumatoid arthritis[36]. SNPs investigated in five or more independent
studies were considered (n = 4). Only ATIC rs2372536
showed a potential association of the minor allele with
toxicity. This SNP did not show an association with
adverse events in our review. Conversely, whereas we
found an association of SLC19A1 rs1051266 with effi-
cacy (though in a single study), results about this SNP
were inconsistent in the adult review. Thus, the results
of the adult and paediatric review were quite different.
This might be due to incomparability of children and
adults in this respect, maybe because of a different meta-
bolization of MTX [37]. On the other hand, it shows
there is still much to do in the field of MTX prediction.
Most SNPs investigated in this review were located in
genes involved in the MTX metabolic pathway. In short,
MTX enters the cell via the members of the SLC protein
family. It becomes polyglutamated by FPGS, causing its
cellular retention. Depolyglutamation is brought about
by GGH. MTX is pumped out of the cell by members of
the ABC transporter family. Intracellular MTX-PGs
exert a range of actions. First, they inhibit DHFR and in-
fluence MTHFR, enzymes in the folate pathway involved
in polyamine synthesis. Secondly, they inhibit TYMS, an
enzyme in the pyrimidine synthesis pathway. Finally, by
blocking ATIC, MTX-PGs stimulate the production of
adenosine, an anti-inflammatory agent. Other important
enzymes in this pathway are ITPA and AMPD1, which
themselves are not influenced by MTX [17,36]. It can be
hypothesized that SNPs in any of these genes cause
increased or decreased sensibility to the actions of
MTX-PGs and hence lead to altered MTX efficacy.
Other potential predictors included the MRP8/14
(S100A8/A9) level, a danger signal and activator of toll-
like receptor 4, which in turn plays a role in the innate
immune response in inflammatory conditions. MRP8/14
was earlier shown to predict disease flare or continua-
tion of remission after withdrawal of MTX in children
who were in remission [5]. Another candidate predictor,
osteopontin, is expressed by natural killer cells and
activated T cells, and plays a role in the production of
pro-inflammatory cytokines. It is overexpressed in syn-
ovial T cells in patients with rheumatoid arthritis, de-
monstrating its role in inflammatory arthritis [26]. The
theoretical background of these candidate predictors
may increase the likelihood that they really affect MTX
efficacy, however, it should be kept in mind that the
found associations do not prove a causal effect.
The most frequently used outcome criteria with re-
spect to MTX efficacy were the American College of
Rheumatology (ACR) response criteria [38]. These cri-
teria, though validated, have their limitations in practical
use. For example, a patient with 69% improvement in all
core set criteria will not be an ACR70 responder,
whereas someone with 70% improvement in three core
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be an ACR70 responder, despite the fact that the former
obviously responds better than the latter. Hence, if one
takes the achievement of ACR70 response status as an
outcome measurement, considerable misclassification
may occur. Alternatively, the percentage of change of the
juvenile arthritis disease activity score (JADAS) could be
used as an outcome measurement to assess MTX efficacy
[39,40]. Because this is a continuous and composite out-
come, the risk of misclassification may be reduced. Re-
cently, the ACR criteria and the JADAS were compared,
showing excellent ability of the JADAS to classify the ACR
response categories [41]. To answer the question which
outcome measurement should be preferred, both mea-
surements should be compared to a reference standard,
such as a panel of experts.
The studies that were analysed in this review were gen-
erally of good quality. They recruited patients at the start
of MTX and followed them prospectively. However, many
articles did not describe whether the studies were blinded,
an absence of which could lead to biases. On a review
level, due to our extensive search strategy, it is likely that
we found all pertinent papers. However, some negative re-
sults might not have been published, leading to reporting
and publication bias. The results found in different studies
were often quite variable. This may be due to heterogen-
eity of patient groups, differences in sample size and the
absence or presence of linkage disequilibrium between the
tested SNP and the actual polymorphism which causes
the altered MTX response [36]. Furthermore, other pa-
tient factors may confound the observed relationship, rea-
son why it is important to perform a multivariate analysis.
This was not done in all studies. Finally, the authors of
this review were co-authors of some of the included pa-
pers, causing them to know more about the study design
and potentially biasing them to be more lenient towards
their own studies.Conclusion
In conclusion, this systematic review of the literature with
respect to predictors for MTX efficacy and adverse events in
JIA patients shows that a number of interesting candidates
were found. However, validation of these potential predic-
tors is still lacking in many cases. Therefore, future efforts
should be directed at validating these candidate predictors,
potentially by means of a clinical prediction model. For the
outcome adverse events, next to validating existing candi-
dates, more candidate predictors should be investigated.Additional files
Additional file 1: Table S1. Results for outcome MTX efficacya.Additional file 2: Table S2. Results for outcome absence of MTX
adverse eventsa.
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